Insulin Efsitora Alfa vs UBT38006
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin Efsitora Alfa · Onswik
Marketed by Eli Lilly
NCT05275400 · Phase 3 · completed
The study randomized 986 participants to efsitora or active-control insulin degludec, but treatment was open-label rather than blinded. The primary HbA1c noninferiority endpoint was met, with a treatment difference of -0.089 percentage points and a 95% confidence interval of -0.191 to 0.013 within the prespecified 0.4% margin; the primary endpoint was a surrogate measure.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Change From Baseline in Hemoglobin A1c (HbA1c) [Noninferiority Analysis] (Baseline, Week 52): Efsitora -1.19 Percentage of HbA1c (Standard Error 0.0546) vs Glargine -1.16 Percentage of HbA1c (Standard Error 0.0545) (met)
Result source: NCT05662332
UBT38006
Developed by United Bio-Technology (Hengqin)
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin Efsitora Alfa | UBT38006 |
|---|---|---|
| HbA1c, change | -1.3% vs -1.2%vs Insulin DegludecNCT0536205811 other results
| —Not reported |
| Body weight, change (kg) | 2.3 vs 2.2vs Insulin DegludecNCT052754006 other results
| —Not reported |
| HbA1c below 7% | —Not reported | —Not reported |
| Fasting plasma glucose, change | —Not reported | —Not reported |
| 3-point MACE (% with event) | —Not reported | —Not reported |
HbA1c, change
- Insulin Efsitora Alfa
- -1.3% vs -1.2%vs Insulin DegludecNCT05362058
11 other results
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.0% vs -1% NCT05462756
- -1.3% vs -1.2% NCT05362058
- -1.2% vs -1.2% NCT05662332
- -0.8% vs -0.7% NCT05275400
- -1.4% vs -1.3% NCT05362058
- -1.0% vs -1% NCT05462756
- -0.6% vs -0.7% NCT03736785
- -0.6% vs -0.7% NCT03736785
- -1.2% vs -1.3% NCT04450394
- UBT38006
- —Not reported
Body weight, change (kg)
- Insulin Efsitora Alfa
- 2.3 vs 2.2vs Insulin DegludecNCT05275400
6 other results
- 3.6 vs 3.5 NCT05362058
- 3.9 vs 3.3 NCT05662332
- 3.2 vs 2.7 NCT05362058
- 2.7 vs 2.5 NCT05462756
- 1 vs 2 NCT03736785
- 1 vs 2 NCT03736785
- UBT38006
- —Not reported
HbA1c below 7%
- Insulin Efsitora Alfa
- —Not reported
- UBT38006
- —Not reported
Fasting plasma glucose, change
- Insulin Efsitora Alfa
- —Not reported
- UBT38006
- —Not reported
3-point MACE (% with event)
- Insulin Efsitora Alfa
- —Not reported
- UBT38006
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
UBT38006: no structured comparison results are available for Type 2 Diabetes.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin Efsitora Alfa: 4 of 4 rows · UBT38006: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin Efsitora Alfa |
|---|---|
| Dropout rate | 9.5%500 U/mLa NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results5.4% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 8.8%Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 4.7% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 12.6%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 12.9%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 1.1%500 U/mLa NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results0.6% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 1.6%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 0%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 0.7%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 0.8%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 15.7%500 U/mLa NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 8 more results8.8% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.5%Efsitora NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 —Insulin Efsitora Alfa NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 6.8% NCT05462756 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.7%LY3209590 Algorithm 1 (Paper) NCT04450394 · Phase 2 · registry result, not featured evidence 7.1%LY3209590 Algorithm 2 (Digital) NCT04450394 · Phase 2 · registry result, not featured evidence 5.2%LY3209590 Algorithm 1 NCT03736785 · Phase 2 · registry result, not featured evidence 6.1%LY3209590 Algorithm 2 NCT03736785 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 500 U/mLa covid-19 10.7% nasopharyngitis 9.2% dose calculation error 6.4% NCT05275400 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 show 7 more resultsnasopharyngitis 9.2% covid-19 7.9% upper respiratory tract infection 7.9% NCT05362058 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 influenza 7.3% covid-19 5.3% hypertension 5.3% NCT05662332 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 4.7% arthralgia 2.3% diarrhoea 2.3% NCT04450394 · Phase 2 · registry result, not featured evidence abdominal discomfort 7.1% anaemia 7.1% chest pain 7.1% NCT04450394 · Phase 2 · registry result, not featured evidence diarrhoea 6.7% upper respiratory tract infection 5.9% cough 0.7% NCT03736785 · Phase 2 · registry result, not featured evidence upper respiratory tract infection 10.6% diarrhoea 6.1% dizziness 5.3% NCT03736785 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin Efsitora Alfa
show 11 more results
show 3 more results
show 4 more results
show 6 more results
show 1 more result
show 4 more results
show 3 more results
show 2 more results
show 1 more result
show 1 more result
show 2 more results
show 2 more results
+ 7 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin Efsitora Alfa's landscape · UBT38006's landscape